Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics
ACHV Price/Volume Stats
| Current price | $4.41 | 52-week high | $10.30 |
| Prev. close | $4.51 | 52-week low | $3.03 |
| Day low | $4.35 | Volume | 82,000 |
| Day high | $4.58 | Avg. volume | 88,132 |
| 50-day MA | $4.42 | Dividend yield | N/A |
| 200-day MA | $4.60 | Market Cap | 151.05M |
ACHV Stock Price Chart Interactive Chart >
Achieve Life Sciences, Inc. (ACHV) Company Bio
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV News From Around the Web
Below are the latest news stories about ACHIEVE LIFE SCIENCES INC that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
ACHV: Not So Fast…By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Update to the Timeline On December 11th, 2023, Achieve Life Sciences, Inc. (NASDAQ:ACHV) filed Form 8-K updating investors on its interactions with the FDA. The company held a pre-new drug application (NDA) meeting with the agency in October regarding cytisinicline, which was followed by additional interaction and written |
Life Science Investor Forum: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv |
TFF Pharmaceuticals Appoints Thomas B. King to Board of DirectorsFORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceu |
LCID Stock Alert: Lucid Announces CFO DepartureLucid stock is falling on Tuesday as investors in LCID react to the company's CFO departing immediately to pursue other opportunities. |
Why Is Achieve Life Sciences (ACHV) Stock Down 44% Today?Achieve Life Sciences stock is falling on Tuesday after the company provided ACHV investors with an FDA update concerning an NDA. |
ACHV Price Returns
| 1-mo | -4.13% |
| 3-mo | -3.08% |
| 6-mo | 9.70% |
| 1-year | -45.42% |
| 3-year | -59.76% |
| 5-year | -94.51% |
| YTD | 7.04% |
| 2023 | 68.16% |
| 2022 | -68.51% |
| 2021 | -3.95% |
| 2020 | -23.57% |
| 2019 | -56.21% |
Loading social stream, please wait...